Skip to contentN
Niagen Bioscience, Inc.
N
NAGENiagen Bioscience, Inc. Q2 2024 · 10-Q
Revenue$22.74M$22.74M+11.9% vs Q2 2023 Net Income-$15.00K-$15.00KN/M vs Q2 2023 EPS Diluted$0.00$0.00N/M vs Q2 2023 Gross Profit$13,693,000+10.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Niagen Bioscience, Inc. · CIK 1386570 · Engraved from SEC EDGAR
Operating Cash Flowderived-$264,000N/M Margins · derivedGross margin60.2%−0.6 pt vs Q2 2023
Operating margin-1.1%+10.3 pt vs Q2 2023
Net margin-0.1%+10.7 pt vs Q2 2023
ended Jun 30, 2024 · filed Aug 7, 2024 · 38 d after period end